
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is in a strong position for success with their focus on treating TRD, a potential for high sales, partnerships, and a strong financial position. With Breakthrough Therapy designation and a CNPV from the FDA, the company has a good chance of approval and commercialization, and risks to achieving this potential include clinical development, competition, and government regulations.
Bears say
Compass Pathways is a biotechnology company that is focused on developing therapies for mental health conditions through the use of their proprietary drug, COMP360, in combination with psychological support. While their development program follows rigorous guidelines and the drug has shown promising results in clinical trials, there are potential challenges with administration and infrastructure requirements that could hinder commercial success. In addition, there are risks associated with FDA and government regulatory oversight, manufacturing, reimbursement, competition, and financing that could impact the company's performance.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares